The CJC-1295 clinical trial showed that a long-acting version raised growth hormone and IGF-1, a hormone that carries many growth-hormone signals. It did not show better sleep, faster recovery, muscle gain, or slower aging. Those are different questions.
The often-cited 2006 paper actually reports two short studies in 66 healthy adults. It tested CJC-1295 alone, with its long-acting attachment. It did not test a CJC-1295/ipamorelin blend.
What the CJC-1295 clinical trial asked
Could a longer-lasting growth-hormone signal keep hormone levels elevated after one injection or a few spaced injections?
CJC-1295 copies GHRH, the body's signal telling the pituitary, a small gland beneath the brain, to release growth hormone. The tested molecule included DAC, short for drug affinity complex. That attachment binds albumin, a protein in blood, helping the molecule remain in circulation.
Sam L. Teichman and colleagues published the original study in the Journal of Clinical Endocrinology & Metabolism in 2006. ConjuChem, the developer, funded the work. Several authors worked for the company.
Who took part, and for how long?
Participants were healthy men and women aged 21–61. They had normal age-adjusted IGF-1 levels. Their BMI, a measure relating weight to height, was 30 or below. These entry requirements kept the study focused on healthy volunteers, rather than people with diagnosed growth-hormone deficiency.
| Study | Participants | Injections studied | Study duration |
|---|---|---|---|
| Single dose | 42: 35 active, 7 placebo | One injection, 30–250 micrograms per kilogram of body weight | 28 days |
| Repeat doses | 24: 20 active, 4 placebo | Two injections 14 days apart, or three 7 days apart; 20–60 micrograms per kilogram | 49 days |
Assignment was random. Participants and researchers did not know who received the drug or placebo, an inactive injection.
What researchers measured
Blood tests tracked drug levels, growth hormone, and IGF-1. Researchers compared peak levels and total hormone exposure over time with placebo. They also recorded symptoms, blood tests, and heart-tracing results.
The main measurements were hormone changes and tolerability. A change in a blood test is not itself a measured improvement in health. This distinction matters when considering a compounded CJC-1295/ipamorelin prescription: the blend was outside this study.
The hormone results, with placebo beside them
After one injection, average growth-hormone levels rose to 2–10 times starting levels for at least six days. Placebo levels stayed relatively stable. Total growth-hormone exposure over seven days was significantly higher than placebo at 60, 125, and 250 micrograms per kilogram.
Average IGF-1 rose to 1.5–3 times starting levels for 9–11 days. After repeat injections, average IGF-1 remained above starting levels through day 28 from the first injection.
The reported half-life—the time it takes the level in the blood to fall by half—was 5.8–8.1 days after one injection. Repeat-dose estimates were 5.4–9.2 days. That describes the DAC molecule's persistence, not how long someone would feel a benefit.
Side effects in the 2006 study were common, though none were serious
Almost everyone receiving a single active injection reported some reaction: 33 of 35 people, compared with 2 of 7 receiving placebo. The researchers described these events as mild or moderate.
This table summarizes the paper's Safety section for the single-dose study:
| Reported event | CJC-1295 | Placebo |
|---|---|---|
| Any adverse event | 94% | 29% |
| Injection-site irritation | About 70% | Described as rare |
| Headache | 63% | 14% |
| Diarrhea | 43% | None reported |
| Flushing, warmth, or temporary low blood pressure | 30% | None reported |
Temporary hives around the injection site occurred in nearly 30% of active recipients and were not dose-related; headache, diarrhea and flushing were more common at the higher doses.
In the repeat-dose study, all 20 active recipients had mild local reactions. Three of four placebo recipients had redness. Flushing ranged from 40% to 100% across active-dose groups; headache ranged from 20% to 80%, versus 50% with placebo. These tiny groups make percentages look more precise than they are.
The paper also reported nausea or abdominal pain in 20% of active recipients. One repeat-dose participant had temporary leg contractions and loss of coordination. Two had temporary dizziness and low blood pressure after their first injection. Both episodes resolved and did not recur after later injections.
Three participants withdrew because of adverse events across the two studies. No serious adverse events or consistent glucose changes were reported. Weeks of observation cannot establish safety over years. These rates also cannot predict reactions to a compounded CJC-1295/ipamorelin blend.
What later studies and reviewers added
A companion paper by Ionescu and Frohman, also in the same journal in 2006, examined overnight hormone patterns in healthy young men. One week after CJC-1295, growth-hormone pulses still occurred. Levels between pulses were 7.5 times higher; average growth hormone rose 46%, and IGF-1 rose 45%. Persistent drug exposure did not mean a completely flat hormone pattern. It still did not establish better recovery or an aging benefit.
As of October 1, 2026, the day this article was written, an August 11, 2026 review in the American Journal of Sports Medicine offered a fresh assessment. It mapped existing studies, rather than testing a new treatment. The authors found that current human trials did not substantiate claims about muscle-and-joint recovery or performance. Its CJC-1295 section identified hormone measurements without corresponding body-composition or healing outcomes.
How the study everyone cites gets misread
A common online shortcut turns the paper into a claim that any product called CJC-1295 lasts a week and builds muscle.
The paper tested the albumin-binding DAC version. The shorter-acting molecule often called CJC-1295 without DAC is modified GRF 1-29, a different GHRH copy without that attachment. The original duration numbers do not transfer. Our CJC-1295 no-DAC explainer covers that naming problem.
Adding ipamorelin introduces another ingredient and another question. The CJC-1295/ipamorelin evidence overview separates ingredient studies from evidence about the combination.
Where the tesamorelin comparison fits
Tesamorelin is another GHRH copy, but its trial question was different. A 2007 New England Journal of Medicine trial measured changes in fat deep inside the abdomen in people with HIV and excess abdominal fat.
That is an example of measuring a physical outcome in a defined patient group. It does not validate CJC-1295, or a compounded tesamorelin/ipamorelin blend. Shared hormone signaling does not make the evidence interchangeable.
What this means for a provider visit
ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in its phase 2 HIV abdominal-fat trial died of a heart attack; FDA's review notes the attending physician thought undiagnosed coronary artery disease the most likely cause. That trial is recorded as terminated. On December 4, 2024, an FDA advisory committee recommended against listing five CJC-1295 substances for compounding, as the official minutes record. The FDA review explainer covers both events.
CJC-1295 is not FDA-approved in any form, according to FDA's November 15, 2024 assessment. A compounded preparation is different from an FDA-approved product: the compounded formulation is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.
The useful discussion connects a treatment goal with evidence, side effects, and follow-up. An IGF-1 result needs age and laboratory context; a higher number alone does not establish better health. The prescriber sets the actual dose and monitoring plan.
At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. The 2006 study informs that conversation; it cannot promise what a compounded prescription will do.
